Australia - English - Department of Health (Therapeutic Goods Administration)

evergrowth pty ltd - propolis resin, quantity: 200 mg/ml (equivalent: lead, qty 2 microgram/ml; equivalent: propolis, qty 300 mg/ml) - liquid, multipurpose - excipient ingredients: propylene glycol - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; decrease/reduce/relieve symptoms of mild mouth ulcers ; traditionally used in chinese medicine to decrease/reduce/relieve mild throat inflammation ; traditionally used in western herbal medicine to decrease/reduce/relieve mild throat inflammation ; decrease/reduce/relieve mild throat inflammation ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of mild throat infection ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild throat infection ; decrease/reduce/relieve throat mucous membrane irritation/inflammation ; helps decrease/reduce/relieve symptoms of minor skin wounds (cuts, scratches and abrasions) ; traditionally used in western herbal medicine to maintain/support wound healing ; traditionally used in chinese medicine to maintain/support wound healing

Australia - English - Department of Health (Therapeutic Goods Administration)

h c l manufacturers pty ltd - propolis dry extract -

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate; maize starch; stearic acid; amaranth aluminium lake; indigo carmine aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; iron oxide yellow; iron oxide red; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; lactose; magnesium stearate; quinoline yellow aluminium lake; brilliant blue fcf aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: stearic acid; magnesium stearate; maize starch; lactose; quinoline yellow aluminium lake; amaranth aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; erythrosine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 3 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

supagas pty limited - piperonyl butoxide; pyrethrins - pressurised spray - piperonyl butoxide benzodioxole active 20.0 g/kg; pyrethrins pyrethroid-pyrethrin active 4.0 g/kg - insecticide - animal housing | domestic premises | factory | food preparation and/or storage area | hospital | hotel and/or motel | bakery | b - ant | beetle | cockroach | crawling insect | fly | flying insect | mosquito | moth | silverfish | adult | adult mosquitoes | ants | argentine ant | cockroachs | fleas | flies | large cockroach | mosquitoes | moths | pharaoh ant | silverfish | small cockroach

Australia - English - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - ascorbic acid,biotin,colecalciferol,cupric sulfate,calcium carbonate,calcium pantothenate,camellia sinensis,chromium picolinate,cyanocobalamin,d-alpha-tocopheryl acid succinate,eleutherococcus senticosus,ferrous fumarate,folic acid,heavy magnesium oxide,manganese amino acid chelate,nicotinamide,pyridoxine hydrochloride,riboflavine,reynoutria japonica,selenomethionine,thiamine nitrate,ubidecarenone,vitis vinifera,zinc oxide -